Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Bassetti, Matteo, Echols, Roger, Matsunaga, Yuko, Ariyasu, Mari, Doi, Yohei, Ferrer, Ricard, Lodise, Thomas P, Naas, Thierry, Niki, Yoshihito, Paterson, David L, Portsmouth, Simon, Torre-Cisneros, Julian, Toyoizumi, Kiichiro, Wunderink, Richard G, Nagata, Tsutae D
Published in The Lancet infectious diseases (01.02.2021)
Published in The Lancet infectious diseases (01.02.2021)
Get full text
Journal Article
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Wunderink, Richard G, Matsunaga, Yuko, Ariyasu, Mari, Clevenbergh, Philippe, Echols, Roger, Kaye, Keith S, Kollef, Marin, Menon, Anju, Pogue, Jason M, Shorr, Andrew F, Timsit, Jean-Francois, Zeitlinger, Markus, Nagata, Tsutae D
Published in The Lancet infectious diseases (01.02.2021)
Published in The Lancet infectious diseases (01.02.2021)
Get full text
Journal Article
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Satlin, Michael J, Simner, Patricia J, Slover, Christine M, Yamano, Yoshinori, Nagata, Tsutae D, Portsmouth, Simon
Published in Antimicrobial agents and chemotherapy (18.07.2023)
Published in Antimicrobial agents and chemotherapy (18.07.2023)
Get full text
Journal Article